Clinical trials: Olfactory Disorders
Anosmia, Covid19
COVID-19 Anosmia Study
To capture the natural history of COVID-19 associated olfactory dysfunction as measured by two patient reported outcome measures (SNOT-22, QOD-NS) and a 6-week BSIT with a comparison to an intervention arm receiving daily omega-3…
- Trial name
- NCT04495816
- Testing
- Omega-3 Fatty Acid Supplement
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Anosmia, Hyposmia
Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
Chronic olfactory dysfunction from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the Unites States affected.
- Conditions
- Anosmia, Hyposmia, Parosmia, Olfactory Disorder
- Trial name
- NCT05445921
- Testing
- Stellate Ganglion Block
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Epilepsy
An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.
This study will assess long-term safety and tolerability of repeat dose diazepam nasal spray in adolescents and adults with cluster seizures, with a focus on potential local effects (changes in nasal mucosa, olfaction, and taste).
- Trial name
- NCT02316847
- Testing
- diazepam nasal spray
- Where
- 33 sites in United States
- Volunteers
- 126 people
- Sponsor
- Acorda Therapeutics
Alzheimer Disease, Mild Cognitive Impairment
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Olfactory identification deficits occur in patients with Alzheimer's disease (AD), are associated with disease severity, predict conversion from mild cognitive impairment (MCI) to AD and are associated with healthy elderly…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
- Trial name
- NCT01951118
- Testing
- Donepezil
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- New York State Psychiatric Institute
Paranasal Sinus Cancer, Nasal Cavity Tumor
A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
This study is being done to test a new treatment plan for large tumors in the sinus or nasal cavity that will include endoscopic surgery plus chemotherapy and proton-beam radiation therapy.
- Conditions
- Paranasal Sinus Cancer, Nasal Cavity Tumor, Nasal Cavity Adenocarcinoma
- Trial name
- NCT03274414
- Testing
- Cisplatin, Adjuvant Proton Radiotherapy, Endoscopic Resection
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Seasonal Allergic Rhinitis
Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis
People with allergies frequently complain of a loss or reduction in the sense of smell. In this study, the investigators propose to perform a randomized, double blind, placebo controlled parallel study of subjects with nasal…
- Trial name
- NCT00361439
- Testing
- Mometasone
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Olfactory Neuroblastoma, Esthesioneuroblastoma
Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).
Background: Olfactory neuroblastoma (ONB) is a rare cancer of the nasal cavity. At diagnosis, it is usually locally advanced. It tends to spread to the neck. Sometimes it spreads to the lungs and bones.
- Conditions
- Olfactory Neuroblastoma, Esthesioneuroblastoma, Neoplasm of the Nasal Cavity
- Trial name
- NCT05012098
- Testing
- Bintrafusp alfa/M7824, Ibuprofen, PET scan
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Migraine Headache
Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)
This study consists of a 4-week screening period, a 24-week treatment period for all participants, followed by a 28-week treatment period extension (to 52 weeks in total) for a subset of at least 60 and up to 80 participants, and…
- Trial name
- NCT03557333
- Testing
- INP104
- Where
- 36 sites in United States
- Volunteers
- 360 people
- Sponsor
- Impel Pharmaceuticals
Head and Neck Cancer, Mucositis
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
RATIONALE: Doxepin hydrochloride may be an effective treatment for oral mucositis pain in patients undergoing radiation therapy with or without chemotherapy.
- Conditions
- Head and Neck Cancer, Mucositis, Oral Complications of Radiation Therapy, Pain
- Trial name
- NCT01156142
- Testing
- doxepin hydrochloride
- Where
- 120 sites in United States
- Volunteers
- 155 people
- Sponsor
- Alliance for Clinical Trials in Oncology
COVID-19-Induced Parosmia
Stellate Ganglion Block for COVID-induced Parosmia
Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the United States affected.
- Trial name
- SGB (NCT06253806)
- Testing
- Stellate Ganglion Block
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Olfactory Dysfunction, COVID-19
Acupuncture Therapy for COVID-Related Olfactory Loss
This study is looking at the role of acupuncture as a treatment for olfactory dysfunction in patients who tested positive for COVID-19.
- Trial name
- NCT04952389
- Testing
- Acupuncture Therapy, Budesonide, Olfactory Training
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Olfactory Disorder, Anosmia
Smell Changes & Efficacy of Nasal Theophylline
This study evaluates the efficacy and safety of nasal theophylline irrigation in treating smell loss related to a viral respiratory infection.
- Conditions
- Olfactory Disorder, Anosmia, Viral Infection, Theophylline Causing Adverse Effects in Therapeutic Use
- Trial name
- SCENT (NCT03990766)
- Testing
- Theophylline, Saline Nasal
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Covid19, Anosmia
Smell in Covid-19 and Efficacy of Nasal Theophylline
Evidence of COVID-19 related anosmia and dysgeusia continues to accumulate daily. Currently, up to 80% of patients report subjective olfactory dysfunction (OD), and prevalence using objective olfactory testing could be even…
- Conditions
- Covid19, Anosmia, Olfactory Disorder, Covid-19 Pandemic
- Trial name
- SCENT2 (NCT04789499)
- Testing
- Theophylline Powder
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Washington University School of Medicine
Covid19, Anosmia
Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)
The main aim of this study is to determine the effects of short-term treatment with hesperidin on COVID-19 symptoms in comparison with a placebo.
- Conditions
- Covid19, Anosmia, Fever, Cough
- Trial name
- Hesperidin (NCT04715932)
- Testing
- Hesperidin
- Where
- Canada
- Volunteers
- 216 people
- Sponsor
- Montreal Heart Institute